ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback